Company news
Tg Therapeutics, Inc. (NASDAQ:TGTX) news
Tg Therapeutics, Inc. news releases on 6ix. Latest, Mar 7, 2025: TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab)…
Press releases — page 2
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
March 6, 2025
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 2, 2025
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 26, 2025
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
February 25, 2025
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
January 13, 2025
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
TG Therapeutics to Participate in the Evercore HealthCONx Conference
November 28, 2024
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
November 20, 2024
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
November 3, 2024
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
October 31, 2024
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
September 17, 2024
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
September 17, 2024
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
September 4, 2024
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
August 5, 2024
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
August 4, 2024
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 6, 2024
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 27, 2024
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
April 30, 2024
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
April 29, 2024
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
April 17, 2024
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 17, 2024
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 14, 2024
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
March 7, 2024
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
February 27, 2024
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
February 26, 2024
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
February 25, 2024
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
February 22, 2024
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 9, 2024
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
January 8, 2024
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
January 8, 2024
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 26, 2023
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
November 2, 2023
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
October 31, 2023
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
October 29, 2023
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
October 11, 2023
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
October 1, 2023
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 6, 2023
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
July 31, 2023
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
July 31, 2023
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
July 30, 2023
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 4, 2023
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
May 31, 2023
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
May 30, 2023
TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 3, 2023
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
April 30, 2023
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
April 27, 2023
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
April 26, 2023
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
April 24, 2023